Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.

Joao Pedro FerreiraAbhinav SharmaFrancisco Vasques-NóvoaAntónio Angélico-GonçalvesAna Rita LeiteMarta Borges-CanhaDavide CarvalhoMilton PackerFaiez ZannadAdelino Leite-MoreiraJoão Sérgio Neves

Published in: European journal of heart failure (2022)

In patients with T2D and cardiovascular disease, albiglutide appeared to have no effect in reducing HF-related events among patients with HF history. These findings, placed in the context of other trials, suggest that GLP1-RA may not improve HF outcomes in patients with HF.

Keyphrases

acute heart failure
heart failure
cardiovascular disease
rheumatoid arthritis
type diabetes
left ventricular
metabolic syndrome
disease activity
coronary artery disease
systemic lupus erythematosus
cardiovascular risk factors
ankylosing spondylitis
idiopathic pulmonary fibrosis
interstitial lung disease